Walleye Capital LLC Buys 266,354 Shares of Dynavax Technologies Corporation $DVAX

Key Points

• Walleye Capital LLC dramatically increased its stake in Dynavax Technologies Corporation by 50,734.1%, owning a total of 266,879 shares valued at approximately $3.46 million as of the most recent SEC filing.
• Dynavax Technologies reported quarterly earnings of $0.14 per share, exceeding analysts' expectations, with revenues of $95.44 million for the quarter.
• Analysts have a consensus rating of "Moderate Buy" for Dynavax Technologies, with an average price target of $24.33 per share.

Walleye Capital LLC grew its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 50,734.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 266,879 shares of the biopharmaceutical company's stock after acquiring an additional 266,354 shares during the quarter. Walleye Capital LLC owned 0.22% of Dynavax Technologies worth $3,461,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of DVAX. DekaBank Deutsche Girozentrale bought a new stake in Dynavax Technologies in the 1st quarter valued at about $30,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of Dynavax Technologies by 5,485.7% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 2,304 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Dynavax Technologies in the fourth quarter valued at approximately $35,000. GAMMA Investing LLC boosted its stake in shares of Dynavax Technologies by 88.4% in the first quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock valued at $100,000 after buying an additional 3,627 shares during the period. Finally, Moloney Securities Asset Management LLC bought a new stake in shares of Dynavax Technologies in the first quarter valued at approximately $131,000. 96.96% of the stock is owned by institutional investors.

Insider Transactions at Dynavax Technologies

In related news, Director Scott Dunseth Myers acquired 3,800 shares of the stock in a transaction dated Friday, August 22nd. The stock was bought at an average cost of $10.82 per share, for a total transaction of $41,116.00. Following the completion of the transaction, the director directly owned 35,004 shares of the company's stock, valued at $378,743.28. The trade was a 12.18% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.98% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

DVAX has been the topic of a number of recent research reports. JMP Securities restated a "market outperform" rating and set a $32.00 price objective on shares of Dynavax Technologies in a research note on Friday, August 22nd. Wall Street Zen upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $24.33.

Dynavax Technologies Price Performance

NASDAQ DVAX traded down $0.15 on Monday, hitting $10.12. 1,164,789 shares of the company's stock were exchanged, compared to its average volume of 1,873,077. Dynavax Technologies Corporation has a 52 week low of $9.22 and a 52 week high of $14.63. The stock has a 50-day moving average of $10.62 and a 200-day moving average of $11.29. The company has a current ratio of 6.65, a quick ratio of 6.01 and a debt-to-equity ratio of 0.45. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -22.00 and a beta of 1.24.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.02. The company had revenue of $95.44 million for the quarter, compared to analyst estimates of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. Analysts expect that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.